Search company, investor...
Caristo Diagnostics company logo

Caristo Diagnostics

Founded Year



Spinoff / Spinout | Alive

About Caristo Diagnostics

Caristo Diagnostics develops cardiovascular diagnostic tools aimed at transforming the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, enhancing the power to predict cardiovascular risk and refine treatment decisions.

Headquarters Location

New Barclay House 234 Botley Road

Oxford, England, OX2 0HP,

United Kingdom

(+44) 1865 950720

Compete with Caristo Diagnostics?

Ensure that your company and products are accurately represented on our platform.

Caristo Diagnostics's Products & Differentiators


    AI-powered image analysis technology that quantifies coronary inflammation and plaque characteristics to predict future heart attack risk

Research containing Caristo Diagnostics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Caristo Diagnostics in 1 CB Insights research brief, most recently on Jun 25, 2021.

Expert Collections containing Caristo Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Caristo Diagnostics is included in 3 Expert Collections, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)


Health Monitoring & Diagnostics

315 items

Companies developing technology for computer-aided diagnostic imaging. Companies tagged as #ComputerAidedDxImaging


Health IT

363 items

Latest Caristo Diagnostics News

AI tool can identify risk of heart attack ‘years before it strikes’

Apr 20, 2021

AI tool can identify risk of heart attack ‘years before it strikes’ An artificial intelligence tool that can identify people at risk of a heart attack years before it strikes is now ready to be rolled out in the NHS. The CaRi-Heart tool, developed by Caristo Diagnostics and based on research funded by the British Heart Foundation (BHF), predicts possible heart disease using routine heart scans. It works by scanning “ticking-time-bomb” arteries that could become clogged to cause a heart attack. Looking at regular heart scans the artificial intelligence (AI) technology produces a ‘fat attenuation index score’ (FAI-Score), which accurately measures inflammation of blood vessels in and around the heart. It’s this inflammation that could eventually lead to a heart attack. Those identified at high risk of a future heart attack can then be given personalised medication, as well as being monitored more closely, to prevent a life-threatening situation. It received its CE accreditation in March and is now ready for use by doctors across the UK and Europe. Dr Cheerag Shirodaria, chief executive officer and co-founder of Caristo Diagnostics, said: “The beauty of our technology is that it will not only save countless lives, but it is incredibly simple. CaRi-Heart analysis can be undertaken on any CT heart scan, hospitals don’t need to change equipment and patients don’t need another test. “Physicians simply need to send their patient’s CT heart scan and they will then receive the personalised FAI-Score and CaRi-Heart Risk to guide patient management. It fits perfectly with a physician’s workflow.” The scientific work that underpins Caristo Diagnostics was initially carried out by BHF researchers at the University of Oxford. The technology was validated in a BHF study with 4000 patients who were followed up for nine years after their original coronary CT angiogram. They found that people with an abnormal FAI were up to nine times more likely to die of a heart attack in the next nine years than those with normal FAI readings. The study also showed that at least one third of patients who underwent a routine coronary CT angiogram and were initially considered low risk had a much higher risk after CaRi-Heart was applied to their scan. Now researchers are looking at ways to use the technology to better predict an individual’s risk of developing stroke and diabetes by analysing routine CT scans. They are also developing an AI tool to specifically identify Covid-19 patients who are at high risk of having a future heart attack or stroke. Professor James Leiper, associate medical director at the British Heart Foundation, said: “The development and approval of this new AI tool is a major success story. It’s a prime example of how BHF-funded research can lay the foundations for a truly transformational advance in the diagnosis and prevention of heart and circulatory diseases. “This research exemplifies the fundamental role medical research charities play in the translation of scientific research into the commercial and clinical sectors, which ultimately benefits the UK’s scientific ecosystem and patients with cardiovascular disease. “Sadly, the pandemic has had a devastating blow to the BHF’s research spend, cutting it in half by £50 million this year alone. We need the kind support of the public more than ever to continue our life-saving research so more projects like this can get off the ground.” Related Posts

Caristo Diagnostics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Caristo Diagnostics Rank

Caristo Diagnostics Frequently Asked Questions (FAQ)

  • When was Caristo Diagnostics founded?

    Caristo Diagnostics was founded in 2018.

  • Where is Caristo Diagnostics's headquarters?

    Caristo Diagnostics's headquarters is located at New Barclay House, Oxford.

  • What is Caristo Diagnostics's latest funding round?

    Caristo Diagnostics's latest funding round is Spinoff / Spinout.

  • Who are the investors of Caristo Diagnostics?

    Investors of Caristo Diagnostics include University of Oxford.

  • Who are Caristo Diagnostics's competitors?

    Competitors of Caristo Diagnostics include Cleerly and 3 more.

  • What products does Caristo Diagnostics offer?

    Caristo Diagnostics's products include CaRi-Heart.

  • Who are Caristo Diagnostics's customers?

    Customers of Caristo Diagnostics include Dr Andrew Mitchell.

Compare Caristo Diagnostics to Competitors

Artrya Logo

Artrya is working to solve the world’s largest cause of death – heart disease. The company is using Artificial Intelligence to more accurately identify patients at risk of Coronary Artery Disease and guide clinicians in delivering more effective treatment.

Elucid Logo

Elucid is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging. Its product, ElucidVivo, is an FDA-cleared & CE-marked, histology-validated, non-invasive image analysis software for evaluating CTAs to provide multi-dimensional visualization, structural measurements, and plaque composition to inform risk of an event (heart attack or stroke) and personalized treatment selection. Elucid was founded in 2009 and is based in Boston, Massachusetts.

HeartFlow Logo

HeartFlow is a digital health company aiming to transform how heart disease is diagnosed and treated. HeartFlow provides a new approach to non-invasive diagnosis of coronary artery disease (CAD), the #1 cause of death. Leveraging deep learning and trained analysts, HeartFlow creates a personalized, digital 3D model of patients’ coronary arteries based on data from CT scans. Physicians use the model to evaluate the impact a blockage has on blood flow to the heart and determine the most optimal treatment pathway for patients.

Cleerly Logo

Cleerly is a healthcare company that uses AI-powered imaging to analyze heart scans and whose mission is to create digital care pathways to prevent heart attacks. The company integrates clinical science with AI in order to offer clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, it aims to provide a comprehensive solution for cardiovascular disease evaluation that offers great value to the healthcare system and improves heart health for patients at risk of heart attacks. The company was founded in 2017 and is based in New York, New York.

Infervision Logo

Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.

Perspectum Logo

Perspectum is a provider of digital technologies that help clinicians provide better care for patients with liver disease. The company's work focuses on the detection and accurate, quantitative measurement of liver, gall bladder, and pacreatic disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.